Tuan Nguyen, MD
Internal Medicine · Norcross, GANPI 1386756955
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 446 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,605 and has fallen 62.9% since, to $595 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$1K
- Lilly USA, LLC$691
- Sanofi-aventis U.S. LLC$564
- Amarin Pharma, Inc.$514
- AstraZeneca$505
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,074100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 75 | $1,387 |
| Novo Nordisk | 68 | $1,207 |
| Lilly USA, LLC | 38 | $691 |
| Sanofi-aventis U.S. LLC | 37 | $564 |
| Amarin Pharma, Inc. | 27 | $514 |
| AstraZeneca | 26 | $505 |
| Kowa Pharmaceuticals America, Inc. | 25 | $374 |
| AbbVie | 21 | $358 |
| Pfizer | 14 | $298 |
| Lundbeck LLC | 13 | $270 |
| Corcept Therapeutics | 10 | $239 |
| Boehringer Ingelheim | 12 | $229 |
| Eisai Inc. | 15 | $221 |
| Gilead | 10 | $191 |
| Abbott | 11 | $178 |
| Sumitomo Pharma America, Inc. | 4 | $138 |
| Esperion Therapeutics, Inc. | 7 | $130 |
| Exact Sciences | 7 | $120 |
| IBSA Pharma Inc. | 6 | $103 |
| Novartis | 4 | $65 |
| GSK | 2 | $46 |
| Alk-abello, Inc | 2 | $39 |
| Merck | 2 | $34 |
| Bayer | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Akcea Therapeutics, Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $24 |
| Bausch Health US, LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,088 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 133 | $197,739 |
| EliquisApixaban | 170 | $79,922 |
| CreonLipase/Protease/Amylase | 35 | $48,951 |
| XareltoRivaroxaban | 95 | $43,182 |
| LinzessLinaclotide | 36 | $33,966 |
| JanuviaSitagliptin Phosphate | 28 | $32,428 |
| MyrbetriqMirabegron | 46 | $29,731 |
| RestasisCyclosporine | 22 | $26,198 |
| VemlidyTenofovir Alafenamide | 13 | $18,228 |
| TradjentaLinagliptin | 14 | $17,621 |
| TrulicityDulaglutide | 15 | $17,145 |
| VascepaIcosapent Ethyl | 22 | $16,367 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $14,191 |
| Diclofenac Sodium | 200 | $10,308 |
| Metformin Er GastricMetformin Hcl | 25 | $9,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $229 | $221,137178 claims |
| AbbVieCreon, Linzess, Restasis, Combigan | $358 | $112,577104 claims |
| PfizerEliquis | $298 | $79,922170 claims |
| Johnson & JohnsonXarelto | $24 | $43,18295 claims |
| MerckJanuvia | $34 | $32,42828 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $46 | $22,68527 claims |
| GileadVemlidy | $191 | $18,22813 claims |
| Lilly USA, LLCTrulicity | $691 | $17,14515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Norcross
- Patrick HuynhNorcross$17K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.